EnsiliTech, a Bristol, UK-based biopharmaceuticals company, raised £1.2m in pre-seed funding.
The round was led by Science Angel Syndicate and Fink Family Office. with participation from QantX, Elbow Beach Capital, angel investors and Innovate UK.
The company intends to use the funds for the development of a refrigeration-free approach to transporting vaccines and other materials.
Led by Co-founder and CEO Dr. Asel Sartbaeva and and CTO Dr. Aswin Doekhie, EnsiliTech has developed patented platform technology – ensilication – that can be applied to both existing and new biopharmaceuticals to make them safe and stable at room temperatures. Ensilication preserves the integrity of vaccines and other biological materials at temperatures that range from -20C to +80C. The company’s technology has the potential to improve the distribution of vaccines and other biological materials in developing countries, where access to reliable refrigeration can be a major barrier to healthcare. It could also have a significant impact on the global effort to combat the ongoing Covid-19 pandemic, by enabling the rapid and safe distribution of vaccines to communities in need.
FinSMEs
17/01/2023